Caraco Pharma announces FDA approval to market generic version of Adipex-P(R) Co announces that the FDA has granted final approval for the Company's Abbreviated New Drug Application for Phentermine Hydrochloride Tablets USP, 37.5 mg. Phentermine HCl is indicated only as short-term monotherapy for the management of exogenous obesity. Firm's generic Phentermine HCl is the bioequivalent to Adipex-P(R), a registered trademark of TEVA Pharmaceuticals USA, Inc. According to IMS Data, for the twelve months ended June 2007, Phentermine HCl generic and brand products (Adipex-P(R)) combined had annual sales of approximately $34 million.
